Myriapod® permits with only one DNA test to identify all SNPs which could give an adverse response to the drugs normally used for a specific neoplastic pathology treatment.
As a consequence, thanks to the technic and fondamental clinical experience, oncologist could better select appropriate and less toxic chemo and radiation treatment for each single patient.

Myriapod® is able to analyse tens of mutations in a single session.
It permits to pass from patient’s DNA to the personalized therapy choice in less than one day.

  • System CE IVD labeled;
  • More than 250 targets in at least 80 genes in parallel;
  • Analysis can be performed from a large range of starting materials: blood samples, fresh, frozen and even FFTP tissues, cellular lines;
  • Accuracy higher than 99,7%;
  • High sensibility: possibility to identify alleles mutated at a less than 10% frequency;
  • Heighten reproducibility and reliability.

The Myriapod kits are available only for the Italian market. For more information please contact us. 

Category

Mass Spectrometry

Validated tools
Labcycler SensoQuest GmbH
MassArray System Agena Bio
Nanodispenser RS1000 Agena Bio
Request information

    Please insert your email address below, we will contact you soon.

    I confirm that I have read the information on the personal data management.

    I agree to the processing of my personal data
    according to the above mentioned information

    *Both options must be selected